Literature DB >> 24667369

Increased eNOS levels in hereditary angioedema.

Mustafa Demirtürk1, Aslı Gelincik2, Suzan Cınar3, Meltem Kilercik4, Evren Onay-Ucar5, Bahattin Çolakoğlu2, Nazli Arda5, Suna Büyüköztürk2, Günnur Deniz3.   

Abstract

BACKGROUND: Hereditary angio-edema (HAE), characterized by recurrent episodes of angioedema involving the skin and the mucosa of the upper respiratory or the gastrointestinal tracts, results from heterozygosity for deficiency of the serine proteinase inhibitor (serpin), C1 inhibitor (C1-INH).
OBJECTIVE: In this study, serum inflammatory cytokine levels and circulating endothelial cells collected from HAE patients during both acute attacks and asymptomatic periods were evaluated.
METHOD: Twenty-four patients with Type I and 1 patient with Type II HAE in an asymptomatic period (Group I), 8 patients with Type I HAE during a mild to moderate acute attack (Group II) and 20 healthy subjects (13 females, mean age: 32.1±8.2years) were included. Serum IL-6, IL-8, IL-1β, TNF-α, vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) levels were detected by ELISA. Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) were evaluated using Fluorescence Activated Cell Sorting (FACS).
RESULTS: Serum eNOS levels of HAE patients were significantly higher than healthy subjects (p<0.006) while mean TNF-α levels in Group I were slightly lower (p<0.03) than Group II. There were no differences in terms of other inflammatory cytokines between the control subjects and HAE patients who were either in an asymptomatic period or experiencing an acute attack. CECs and CEPs were also similar.
CONCLUSION: These results suggest that an inflammatory response is not necessary to trigger HAE attacks. On the other hand, increased eNOS levels might reflect a sustained hyperpermeability state in HAE patients.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C1 inhibitor (C1-INH); Endothelial nitric oxide synthase (eNOS); Hereditary angio-edema (HAE); Inflammatory cytokines

Mesh:

Substances:

Year:  2014        PMID: 24667369     DOI: 10.1016/j.intimp.2014.03.007

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

Review 1.  HAE Pathophysiology and Underlying Mechanisms.

Authors:  Bruce L Zuraw; Sandra C Christiansen
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

2.  Serum fetuin-A, tumor necrosis factor alpha and C-reactive protein concentrations in patients with hereditary angioedema with C1-inhibitor deficiency.

Authors:  Bernadett Márkus; Nóra Veszeli; György Temesszentandrási; Henriette Farkas; László Kalabay
Journal:  Orphanet J Rare Dis       Date:  2019-03-18       Impact factor: 4.123

3.  Oxidative stress markers in patients with hereditary angioedema.

Authors:  Stefano R Del Giacco; Davide Firinu; Paola Lucia Minciullo; Maria Pina Barca; Paolo Emilio Manconi; Gennaro Tartarisco; Mariateresa Cristani; Antonella Saija; Sebastiano Gangemi
Journal:  Arch Med Sci       Date:  2017-07-31       Impact factor: 3.318

4.  Exhaled Nitric Oxide Level in Pharynx Angioedema.

Authors:  Łukasz Moos; Magdalena Zajac; Zenon Brzoza
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

5.  Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency.

Authors:  Nóra Veszeli; Dorottya Csuka; Zsuzsanna Zotter; Éva Imreh; Mihály Józsi; Szabolcs Benedek; Lilian Varga; Henriette Farkas
Journal:  Orphanet J Rare Dis       Date:  2015-12-10       Impact factor: 4.123

6.  Impaired Endothelial Function in Hereditary Angioedema During the Symptom-Free Period.

Authors:  Davide Firinu; Pier P Bassareo; Angela M Zedda; Maria P Barca; Antonio Crisafulli; Giuseppe Mercuro; Stefano Del Giacco
Journal:  Front Physiol       Date:  2018-05-16       Impact factor: 4.566

Review 7.  Biomarkers in Hereditary Angioedema.

Authors:  Grzegorz Porebski; Mateusz Kwitniewski; Avner Reshef
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-09       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.